$REPL
Replimune Group, Inc.
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$13.09
▲+1.72%+$0.222
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateReplimune Group, Inc.
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is REPL up today? It is at $13.09 (+1.72%), and our scanner flagged it 68 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment REPL spikes, and full due diligence on REPL — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $REPL 68 times in the last 30 days. Create a free account to track $REPL, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on REPL from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for REPL today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystCharter / Bylaw Change · Shareholder Vote, from the latest SEC filing. Read it →A share sale has already completed, so that supply is out there. Size not stated in the filing.
Some filings did not state a size, so these are floors.
Recent share offering + active shelf on file — the company raised capital and can raise more
12,437,830 new shares
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Astley-Sparke Philip Director | Sold (automatic/other) | -50K 0.05% of company | sold 3.5% | 1.36M | n/a | Aug 20, 26 |
Hill Emily Luisa Officer | Sold (automatic/other) | -9K | sold 4.1% | 216K | $132K at $14.28 | Aug 17, 26 |
Schwendenman Andrew Officer | Sold (automatic/other) | -8K | sold 7.1% | 99K | $99K at $12.97 | Aug 10, 26 |
Xynos Konstantinos Officer | Sold (automatic/other) | -11K 0.01% of company | sold 4.9% | 224K | $148K at $12.97 | Aug 10, 26 |
Hill Emily Luisa Officer | Sold (automatic/other) | -11K 0.01% of company | sold 4.8% | 225K | $148K at $12.97 | Aug 10, 26 |
Patel Sushil Officer | Sold (automatic/other) | -39K 0.04% of company | sold 5.3% | 708K | $510K at $12.97 | Aug 10, 26 |
Sarchi Christopher Officer | Sold (automatic/other) | -12K 0.01% of company | sold 6.2% | 181K | $111K at $9.24 | Jun 1, 26 |
Hill Emily Luisa Officer | Sold (automatic/other) | -8K | sold 3.2% | 237K | $40K at $5.08 | May 18, 26 |
Patel Sushil Officer | Sold (automatic/other) | -37K 0.04% of company | sold 4.8% | 747K | $190K at $5.08 | May 18, 26 |
Astley-Sparke Philip Director | Sold (automatic/other) | -18K 0.02% of company | sold 1.2% | 1.41M | $90K at $5.08 | May 18, 26 |
Sarchi Christopher Officer | Sold (automatic/other) | -9K | sold 4.3% | 193K | $44K at $5.08 | May 18, 26 |
Schwendenman Andrew Officer | Sold (automatic/other) | -8K | sold 6.9% | 107K | $40K at $5.08 | May 18, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on REPL from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for REPL today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
REPL last traded at $13.09, up 1.72% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Replimune Group, Inc. (REPL) is next expected to report earnings on Thursday, November 5, 2026, about 46 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The REPL Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged REPL 68 times in the last 30 days.
REPL (Replimune Group, Inc.) trades on XNAS, with a market cap of about $1.23B in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge REPL for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$REPL discussion
Sign in to ask a question or join the discussion.